Ximelagatran (Exanta): Alternative to Warfarin?

This publication has 12 references indexed in Scilit:

• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
  The Lancet, 2003
• Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
  New England Journal of Medicine, 2003
• Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement
  New England Journal of Medicine, 2003
• Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study
  Journal of Thrombosis and Haemostasis, 2003
• Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
  American Heart Journal, 2003
• The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review
  Thrombosis Research, 2003
• Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation
  JACC, 2003
• Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects
  European Journal of Clinical Pharmacology, 2003
• Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement
  Thrombosis and Haemostasis, 2003
• Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial
  The Lancet, 2002